SKK
PGNX

Shepherd Kaplan Krochuk’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,497
Closed -$117K – 451
2015
Q3 		$117K Buy
+20,497
New +$157K 0.03% 321

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shepherd Kaplan Krochuk's PGNX Position: Q4 2015 in Review

Shepherd Kaplan Krochuk sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2015, closing a stake of 20,497 shares — an estimated $117K sold.

Shepherd Kaplan Krochuk first reported a position in PGNX in Q3 2015 and held it in 1 quarter. The position peaked at $117K in Q3 2015. 121 funds tracked by Wall St. Rank hold PGNX as of Q4 2015.

  • Shepherd Kaplan Krochuk reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 20,497 Progenics Pharmaceuticals Inc shares in Q4 2015, an estimated $117K.
  • Shepherd Kaplan Krochuk first reported a position in Progenics Pharmaceuticals Inc in Q3 2015 and held it in 1 quarter.
  • Shepherd Kaplan Krochuk's Progenics Pharmaceuticals Inc position peaked at $117K in Q3 2015.
  • 121 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2015.

Based on Shepherd Kaplan Krochuk's 13F filing for Q4 2015, filed 16 Feb 2016.